On July 9, 2025, Ultragenyx Pharmaceutical Inc. reported that the Phase 3 Orbit study for UX143 (setrusumab) is progressing well, with an acceptable safety profile in young patients with osteogenesis imperfecta, and is set for final analysis by year-end.